Tirzepatide (10mg) – TR10

Tirzepatide (10mg) — Research Peptide

Tirzepatide is a synthetic, acylated 39-amino acid peptide that functions as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Developed by Eli Lilly, tirzepatide has received regulatory approval in multiple jurisdictions (FDA approval as Mounjaro for type 2 diabetes; Zepbound for obesity) and has generated one of the most extensive clinical trial datasets of any incretin-based compound — making it an important reference point in GLP-1 class research.

Dual Receptor Mechanism

GIP receptor (GIPR) agonism: GIP is an incretin hormone secreted by duodenal K-cells in response to nutrient ingestion. GIPR agonism potentiates insulin secretion, promotes adipose tissue energy storage and lipid clearance, and in combination with GLP-1R agonism, appears to improve the tolerability profile of GLP-1 class compounds. The precise contribution of GIPR agonism to tirzepatide’s clinical outcomes remains an active area of research.

GLP-1 receptor (GLP-1R) agonism: Shared mechanism with semaglutide — enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce energy intake.

Clinical Research Context

The SURPASS clinical programme (SURPASS-1 through SURPASS-6) and the SURMOUNT programme for obesity have generated extensive Phase 3 data, including head-to-head comparisons with semaglutide (SURPASS-2) showing tirzepatide’s superior HbA1c and body weight reduction outcomes at matched doses — data that has driven significant research interest in GIP/GLP-1 dual agonism.

Product Specifications

• Peptide: Tirzepatide (dual GIP/GLP-1 receptor agonist)
• Dose: 10mg per vial
• Format: Lyophilised powder, bulk box of 10 vials
• Purity: ≥98% Janoshik HPLC verified
• Storage: -20°C. 24-month stability.

For laboratory research use only. Not for human therapeutic use outside approved indications.